Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)


Avibactam, a novel β-lactamase inhibitor, has recently been co-formulated with ceftazidime and approved for use in patients with complicated intra-abdominal and urinary tract infections, where no better treatment alternative exists. The basis for its FDA approval has been the extensive clinical experience with ceftazidime and the demonstration in vitro and in animal models that the addition of avibactam reverses resistance to ceftazidime in extended-spectrum β-lactamase and some carbapenemase-producing Enterobacteriaceae. Early clinical data are promising, with efficacy demonstrated in patients with complicated intra-abdominal and urinary tract infections. This review will summarize the in vitro, animal and clinical data available on this agent to date.

Original languageEnglish
Pages (from-to)451-463
Number of pages13
JournalExpert Review of Anti-Infective Therapy
Issue number5
Publication statusPublished - 2016
Externally publishedYes


  • antibiotic resistance
  • carbapenem-resistant Enterobacteriaceae
  • Ceftazidime-avibactam
  • Gram-negative infection
  • β-lactamase
  • β-lactamase inhibitor

Cite this